XTX Topco Ltd Purchases 117,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

XTX Topco Ltd grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 299.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 156,946 shares of the biotechnology company’s stock after buying an additional 117,607 shares during the period. XTX Topco Ltd owned 0.08% of BioCryst Pharmaceuticals worth $970,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of BCRX. CWM LLC increased its position in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares during the last quarter. Signaturefd LLC boosted its stake in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,599 shares in the last quarter. Quarry LP purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $54,000. Seven Eight Capital LP purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $57,000. Finally, Natixis raised its holdings in shares of BioCryst Pharmaceuticals by 400.6% during the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 9,350 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 0.5 %

BCRX stock opened at $8.11 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $8.88. The stock has a market cap of $1.67 billion, a P/E ratio of -7.58 and a beta of 1.88. The business’s 50-day moving average price is $7.79 and its 200-day moving average price is $6.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. During the same period in the previous year, the firm earned ($0.24) earnings per share. The firm’s quarterly revenue was up 34.9% on a year-over-year basis. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Amy E. Mckee sold 8,600 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $6.32, for a total value of $54,352.00. Following the transaction, the director now directly owns 27,831 shares of the company’s stock, valued at approximately $175,891.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BCRX. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Barclays raised their price target on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. JMP Securities raised their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $14.17.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.